Nektar Therapeutics Archives -

Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in

After bempeg failure, Nektar wields the axe

https://pharmaphorum.com/news/after-bempeg-failure-nektar-wields-the-axe/

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar’s bempegaldesleukin a companion drug to its

End of the line for BMS, Nektar’s bempegaldesleukin/Opdivo alliance

https://pharmaphorum.com/news/end-of-the-line-for-bms-nektars-bempegaldesleukin-alliance/

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar’s bempegaldesleukin, setting it up

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

https://pharmaphorum.com/news/sour-taste-for-nektar-as-bempegaldesleukin-flunks-ph3-test/

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers

Nektar lifted by Merck alliance for bempeg, new trial funding

https://pharmaphorum.com/news/nektar-lifted-by-merck-alliance-for-bempeg-new-trial-funding/

Nektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory

Nektar pulls pain drug after bruising FDA panel meeting

https://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

https://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/

Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it

BMS makes record $1.8bn bet on Nektar cancer drug

https://pharmaphorum.com/news/bms-makes-record-1-8bn-bet-on-nektar-cancer-drug/

BMS and Nektar’s combination latest in frenzied immunotherapy field

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

Nektar Therapeutics